Tumour Characterisation to Guide Experimental Targeted Therapy - National
The primary aim of TARGET National is to establish a national framework to offer molecular profiling of circulating tumour DNA and/or tumour tissue (optional) to patients with advanced solid cancers referred to any of the Experimental Cancer Medicine Centres (ECMCs) across the UK, in order to help decision making for allocation to molecularly targeted experimental cancer treatments. Patients will be allocated treatment using a national Molecular Tumour Board to find the most suited therapies based on their molecular profiling results.
This study aims to recruit up to 6,000 patients with advanced solid tumours across 5 years and proposes to collect blood samples, archival tumour tissue and fresh tissue (optional)
The data may also be used for future development of predictive cancer biological markers, the design of clinical trials involving new or existing drugs, discovery of new genetic targets and exploring how resistance to specific anticancer agents arises in patients to help improve future cancer treatment management.
|Condition or Disease||Intervention/Treatment||Phase|
Primary Outcome Measures
- To determine the number of patients matched to a trial of an experimental therapeutic agent based on molecular findings from ctDNA or tumour [5 years]
Secondary Outcome Measures
- Number of patients and cancer types with successful result obtained from ctDNA. [5 years]
- Turnaround times from date of patient consent to date of genomic tumour profiling report generation. [5 years]
- Number and range of molecular alterations found in blood (and/or tumour) of cancer patients referred to Experimental Cancer Medicine Centres. [5 years]
- Overall response rates of patients who commence on a trial of an experimental therapeutic agent (matched or unmatched) on the basis of molecular findings in this study). [5 years]
- Progression-free survival of patients who commence on a trial of an experimental therapeutic agent (matched or unmatched on the basis of molecular findings in this study). [5 years]
- Overall survival of patients who commence on a trial of an experimental therapeutic agent (matched or unmatched on the basis of molecular findings in this study). [5 years]
Aged 16 years or over.
Written informed consent according to GCP and national regulations.
Patients with confirmed histological or cytological diagnosis of advanced solid cancer who have been referred to any of the ECMCs in the UK AND considered fit enough to receive an experimental therapeutic agent.
Availability of archival tumour sample (if tumour profiling is required)
Willingness to provide blood samples during the course of the study if allocated to a matched experimental therapy.
Known HIV, Hepatitis B (defined as Hepatitis B surface antigen [HBsAg] reactive) or Hepatitis C virus (defined as HCV RNA detected), due to the difficulties in handling high-risk specimens. Routine testing for hepatitis is not required. Note: Patients with past/resolved Hepatitis B infection (defined as having a negative HBsAg test and a positive antibody to hepatitis B core antigen [anti-HBc] antibody test) are eligible. Patients with a history of Hepatitis C infection are eligible only if polymerase chain reaction (PCR) analysis is negative for HCV RNA at least 6 months after completing treatment for Hepatitis C infection.
Known current COVID19 positive (by PCR) or active symptoms for COVID19. Routine testing for COVID19 is not required. Patients with past infection who have fully recovered may be included.
Patients who are unable to provide fully informed written consent.
Patients not considered eligible by the investigator for early phase clinical trials.
Patients currently receiving systemic anti-cancer therapy (due to potential impact on ctDNA analysis), unless patient has clear evidence of progression on hormone-based therapies or tyrosine kinase inhibitors. A minimum of 3 weeks is required post completion of other systemic anti-cancer therapies.
Presence of any medical, psychological, familial or sociological condition that, in the investigator's opinion, will hamper compliance with the study protocol and follow-up schedule.
Bleeding diathesis (patients' on anticoagulation are permitted to enter the trial if anticoagulation can be safely managed to enable fresh tumour biopsies and blood sampling).
Conditions in which research biopsies or blood sampling may increase risk of complications for the patients and/or investigator
Contacts and Locations
|1||Queen's University Belfast||Belfast||United Kingdom||BT7 1NN|
|2||Cambridge University Hospitals NHS Foundation Trust||Cambridge||United Kingdom||CB20QQ|
|3||Western General Hospital Edinburgh Cancer Centre||Edinburgh||United Kingdom||EH2 2SP|
|4||Beatson West of Scotland Cancer Centre||Glasgow||United Kingdom||G12 0YN|
|5||St.James's University Hospital||Leeds||United Kingdom||LS97TF|
|6||The Christie NHS Foundation Trust||Manchester||United Kingdom||M20 4BX|
|7||The Newcastle Upon Tyne NHS Foundation Trust||Newcastle||United Kingdom||NE7 7DN|
|8||Sheffield University Hospitals NHS Foundation Trust||Sheffield||United Kingdom||S5 7AU|
|9||The Clatterbridge Cancer Centre NHS Foundation Trust||Wirral||United Kingdom||CH63 4JY|
Sponsors and Collaborators
- The Christie NHS Foundation Trust
Study Documents (Full-Text)None provided.